Managers / Q1 2025 · view latest →
MIC Capital Management UK LLP
CIK 0001889830 · FLOOR 7, 25 BERKELEY SQUARE, LONDON, X0, W1J 6HN · (44)02039094610
Summary
Mic Capital Management UK LLP reported $491M in U.S.-listed holdings across 17 positions for Q1 2025.
The portfolio is heavily concentrated: HAYW alone accounts for 28.4% of reported value.
Compared with Q4 2024, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 67.7% · $332M
- Other · 28.3% · $139M
- ADR · 4.0% · $20M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| METSERA INC | NEW | +4.54M | 4.54M | +$124M | $124M |
| ENDEAVOR GROUP HLDGS INC | SOLD OUT | −8.54M | 0 | −$267M | $0 |
| SPORTRADAR GROUP AG | TRIMMED | −265.9K | 660.0K | −$2M | $14M |
| NMRANEUMORA THERAPEUTICS INC. | HELD | +0 | 4.46M | −$43M | $4M |
| RXRXRECURSION PHARMACEUTICALS IN | HELD | −1 | 9.64M | −$14M | $51M |
| HAYWHAYWARD HLDGS INC | HELD | +0 | 10.00M | −$14M | $139M |
| BABAALIBABA GROUP HLDG LTD | HELD | +0 | 150.0K | +$7M | $20M |
| RVMDREVOLUTION MEDICINES INC | HELD | +0 | 508.6K | −$4M | $18M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | HAYWHAYWARD HLDGS INChistory → | COM | 28.35% | $139M | 10.00M |
| 2 | METSERA INC | COM | 25.18% | $124M | 4.54M |
| 3 | RXRXRECURSION PHARMACEUTICALS INhistory → | CL A | 10.39% | $51M | 9.64M |
| 4 | CPNGCOUPANG INChistory → | CL A | 6.31% | $31M | 1.41M |
| 5 | QSRRESTAURANT BRANDS INTL INChistory → | COM | 5.24% | $26M | 386.2K |
| 6 | GRABGRAB HOLDINGS LIMITEDhistory → | CLASS A ORD | 4.61% | $23M | 5.00M |
| 7 | BABAALIBABA GROUP HLDG LTDhistory → | SPONSORED ADS | 4.04% | $20M | 150.0K |
| 8 | METAMETA PLATFORMS INChistory → | CL A | 3.91% | $19M | 33.3K |
| 9 | RVMDREVOLUTION MEDICINES INChistory → | COM | 3.66% | $18M | 508.6K |
| 10 | MNDYMONDAY COM LTDhistory → | SHS | 3.27% | $16M | 66.0K |
| 11 | SPORTRADAR GROUP AG | CLASS A ORD SHS | 2.91% | $14M | 660.0K |
| 12 | ACHRARCHER AVIATION INChistory → | COM CL A | 1.01% | $5M | 700.0K |
| 13 | NMRANEUMORA THERAPEUTICS INC. | COM | 0.91% | $4M | 4.46M |
| 14 | LYELL IMMUNOPHARMA INC | COM | 0.19% | $936,426 | 1.74M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $352M | 18 | May 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $441M | 13 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $500M | 13 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $509M | 16 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $491M | 17 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $706M | 18 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $720M | 15 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $460M | 12 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $527M | 19 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $515M | 19 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $439M | 23 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $492M | 22 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $524M | 25 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $507M | 24 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $555M | 24 | Nov 15, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2022 | $511M | 24 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $514M | 23 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $523M | 23 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.